Week In Review: BGI Genomics Completes $81-Million Chi-Next IPO

At the IPO price, BGI’s valuation was $802 million … Trials and Approvals Canada’s Resverlogix (OTCPK:RVXCF) has begun a Phase III trial in Taiwan of its lead drug, apabetalone, in high-risk patients with cardiovascular disease and type 2 diabetes.
( read original story …)

Search your Hotel